Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.

You may also be interested in...



Chart: Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind

One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).

Lilly Puts On A Happy Face, But Will Investors Buy In?

It was all about the pipeline during Eli Lilly's fourth quarter earnings call, as company execs strove to convince analysts they can compensate for revenue losses from big-ticket products about to lose patent protection

Diabetes: Dueling GLP-1 Agonists And, Perhaps, A Giant Step For Mannkind

One of the biggest potential marketing battles of 2010 is brewing in the GLP-1 agonist market between Novo Nordisk's Victoza (liraglutide), approved on Jan. 25, and Lilly/Amylin/Alkermes' pending once-weekly formulation of Byetta (exenatide).

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel